Pfizer's "mild" first-quarter report is unlikely to satisfy skeptics, an expert said Tuesday. But Pfizer stock recovered and closed higher.

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

For the quarter ended March 2026, Pfizer (PFE) reported revenue of $14.45 billion, up 5.4% over the same period last year. EPS came in at $0.75, compared to $0.92 in the year-ago quarter. The reported ...

Q1 earnings May 4: analyst EPS/revenue estimates, 2026 guidance focus, oncology & obesity pipeline catalysts, and cost cuts.

Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of ...

Pfizer has spent the past few years trying to convince investors that its post-pandemic business can stand on its own, and ...

Second-quarter 2025 Cost of Sales(3) as a percentage of revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision ...

Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively, Friday after a report that the Trump administration plans to link the deaths of 25 children to COVID vaccines. Trump health officials ...

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...